Alzheimer’s disease

In vivo characterization of antibodies directed against TREAT-AD target proteins in mouse model of AD pathology

Posted onAuthorElizabeth ZoellerLeave a comment

In vivo characterization of antibodies directed against TREAT-AD target proteins in mouse model of AD pathology Suzanne Doolen, Riham Ayoubi, Carl Laflamme, Ranjita Betarbet, Elizabeth Zoeller, Sean-Paul G. Williams and Stacey J. Sukoff Rizzo https://doi.org/10.5281/zenodo.6612215 Our goal in support of the Emory-Sage-Structural Genomics Consortium (SGC) TREAT-AD Center is to develop and identify high-quality tools to Read More …

Tandem Microwave-Facilitated Synthesis of Ether-Containing Oxadiazoles

Posted onAuthorDavid RogersLeave a comment

Tandem Microwave-Facilitated Synthesis of Ether-Containing Oxadiazoles David A. Rogers and Kevin J. Frankowski https://doi.org/10.5281/zenodo.6036677 The National Institute on Aging has made a significant commitment to improving the treatment of Alzheimer’s disease through the funding of the TREAT-AD network (Target Enablement to Accelerate Therapy Development for AD, https://treatad.org/). One of the goals of TREAT-AD is to create Read More …

Differential Expression of CD44 Variants in Normal and AD Brain

Posted onAuthorRachel CommanderLeave a comment

 Kun Qian, Ranjita Betarbet, Rachel Commander, Erik Johnson, Opher Gileadi, Haian Fu, and Allan Levey https://doi.org/10.5281/zenodo.4900586 Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, characterized by two pathological hallmarks – extracellular amyloid plaques that are made up of amyloid-peptide and intracellular neurofibrillary tangles that are comprised of hyperphosphorylated tau. AD neuropathology, however, begins decades before Read More …

Fused tetrahydroquinolines (THQ): potential PAINS compounds in a recent HTS for moesin-CD44 pathway inhibitors

Posted onAuthorJoel Annor GyamfiLeave a comment

Joel K. Annor-Gyamfi, Felix Nwogbo, Kun Qian, Yuhong Du, Kenneth H. Pearce Jr, Opher Gileadi, Haian Fu, Stephen V. Frye and Alison D. Axtman https://doi.org/10.5281/zenodo.4685122 Alzheimer’s disease (AD) is the most common cause of dementia worldwide but very few therapeutic options exist despite multiple high-profile but failed clinical trials. And as the population of the Read More …

The Preparation of Allosteric SYK Inhibitor X1 and Investigation of a Covalent Inhibition Mechanism

Posted onAuthorFrances PotjewydLeave a comment

Frances M. Potjewyd and Vittorio Katis http://doi.org/10.5281/zenodo.4670214 Spleen Tyrosine Kinase (SYK) has a reported role in AD pathology and was identified as a target for the TREAT-AD (Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease) program.1–3 We are focusing drug discovery efforts on the inhibition of SYK and more specifically, inhibition of the interaction Read More …

Preparation of the Soluble Epoxide Inhibitor SWE101 and the DOCK1 inhibitor TBOPP

Posted onAuthorDavid RogersLeave a comment

Preparation of the Soluble Epoxide Inhibitor SWE101 and the DOCK1 inhibitor TBOPP David A. Rogers and Kevin J. Frankowski https://doi.org/10.5281/zenodo.4637834 The National Institute on Aging has made a significant commitment to improving the treatment of Alzheimer’s disease through the funding of the TREAT-AD network (Target Enablement to Accelerate Therapy Development for AD, https://treatad.org/). One of Read More …

Towards a GTPase/GEF assay. Background.

Posted onAuthorCarmen Jimenez AntunezLeave a comment

Hi, My name is Carmen, and I a postdoc at the SGC in Oxford. I work in multidisciplinary projects in Paul Brennan and Opher Gileadi groups. Today I am going to introduce one of the projects I have been working for the last year which is part of the group’s endeavour to target small GTPases Read More …

Introducing the team: The Gileadi Group in Oxford.

Posted onAuthorOpher GileadiLeave a comment

Hi! I’m Opher Gileadi, I head a group at the Structural Genomics Consortium (SGC) in Oxford. For many years, we’ve been looking at proteins involved in human. We’ve looked at a wide variety of proteins: from DNA repair enzymes and transcription factors to enzymes involved in signalling. In most cases, we focus on early work: Read More …